Anzeige
Mehr »
Login
Donnerstag, 24.04.2025 Börsentäglich über 12.000 News von 692 internationalen Medien
Jetzt knallt's an der Börse! Diese Aktie hat das Zeug zum Überflieger!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A40J1L | ISIN: CA22112H1010 | Ticker-Symbol: ET8
Frankfurt
23.04.25
08:04 Uhr
2,520 Euro
0,000
0,00 %
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
COSCIENS BIOPHARMA INC Chart 1 Jahr
5-Tage-Chart
COSCIENS BIOPHARMA INC 5-Tage-Chart
RealtimeGeldBriefZeit
2,5402,78016:15

Aktuelle News zur COSCIENS BIOPHARMA Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
14.04.Cosciens Biopharma Inc: Cosciens Biopharma appoints Biehn as CEO4
COSCIENS BIOPHARMA Aktie jetzt für 0€ handeln
14.04.COSCIENS Biopharma ernennt Anna Biehn zur neuen CEO4
14.04.COSCIENS Biopharma names Anna Biehn as new CEO1
14.04.COSCIENS Biopharma Inc. Appoints Global Consumer Products and Biosciences Executive, Anna Biehn as Chief Executive Officer13725+ years of experience in executive leadership roles and developing global strategic growth plans with repeatable models applicable across markets, categories and channels Current President and CEO...
► Artikel lesen
09.04.COSCIENS Biopharma Inc. - 20-F, Annual and transition report of foreign private issuers3
09.04.COSCIENS Biopharma Inc. - 6-K, Report of foreign issuer2
09.04.COSCIENS Biopharma Inc. Reports Fourth Quarter and Full Year 2024 Financial Results and Provides a Corporate Update152Fully repositioned as a pure-play natural-based product company following strategic review and pipeline prioritization Ongoing streamlined efficiencies and cost cutting measures taken to refine operations...
► Artikel lesen
02.04.COSCIENS Biopharma Inc. - 6-K, Report of foreign issuer4
02.04.Cosciens Biopharma Inc: Cosciens receives management cease trade order2
02.04.COSCIENS Biopharma Inc. Announces Receipt of Management Cease Trade Order7
21.03.Why COSCIENS Biopharma Inc. (CSCI) Went Down On Thursday?6
20.03.COSCIENS Biopharma Inc. Announces Possible Delay in Filing Year-End Reporting Documents411Toronto, Ontario--(Newsfile Corp. - March 19, 2025) - COSCIENS Biopharma Inc. (NASDAQ: CSCI) (TSX: CSCI) ("COSCIENS" or the "Company"), a life science company which develops and commercializes a diversified...
► Artikel lesen
20.03.Cosciens Biopharma Inc: Cosciens Biopharma may delay filing 2024 financials3
13.03.Cosciens Biopharma Inc: Cosciens starts phase 2a study on avenanthramides5
13.03.COSCIENS Biopharma Advances Avenanthramide Clinical Trial To Phase 2a For Inflammation Treatment5
13.03.COSCIENS Biopharma Inc. - 6-K, Report of foreign issuer1
13.03.COSCIENS Biopharma Inc. Announces Successful Phase 1 Results Supporting Initiation of Phase 2a Clinical Efficacy Trial with Avenanthramides as a Potential Anti-Inflammatory Product149No significant clinical adverse event observed in Phase 1clinical studyPharmacokinetic profile established and range of doses selected for Phase 2a Clinical Efficacy StudyFirst patient expected to...
► Artikel lesen
23.12.24Cosciens Biopharma Inc: Cosciens talks cost-cutting in 2024, focus for 202511
23.12.24COSCIENS Biopharma halts investment in macimorelin; CMO to depart17
23.12.24COSCIENS Biopharma Inc. Provides Corporate Update and Highlights Pipeline Prioritization306Company leveraging core competencies to develop and commercialize natural-based products to improve health and wellness Streamlined efficiencies and cost cutting measures taken to refine operations...
► Artikel lesen
Seite:  Weiter >>
43 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
2,1,15